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SummarySynchrotron microbeam ra-
diation therapy (MRT) is a
unique treatment that
spatially distributes the x-ray
beam into several micro-
beams of very high dose.
MRT significantly delays
tumor regrowth compared
with uniform radiation ther-
apy. The underlying mecha-
nisms include tumor vascular
disruption, senescence, and
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https://doi.org/10.1016/j.ijrobp.2019.08.027Purpose: Synchrotron microbeam radiation therapy (MRT) is a method that spatially
distributes the x-ray beam into several microbeams of very high dose (peak dose),
regularly separated by low-dose intervals (valley dose). MRT selectively spares normal
tissues, relative to conventional (uniform broad beam [BB]) radiation therapy.
Methods and Materials: To evaluate the effect of MRT on radioresistant melanoma,
B16-F10 murine melanomas were implanted into mice ears. Tumors were either
treated with MRT (407.6 Gy peak; 6.2 Gy valley dose) or uniform BB irradiation
(6.2 Gy).
Results: MRT induced significantly longer tumor regrowth delay than did BB irradi-
ation. A significant 24% reduction in blood vessel perfusion was observed 5 days after
MRT, and the cell proliferation index was significantly lower in melanomas treated by
MRT compared with BB. MRT provoked a greater induction of senescence in mela-
noma cells. Bio-Plex analyses revealed enhanced concentration of monocyte-
attracting chemokines in the MRT group: MCP-1 at D5, MIP-1a, MIP-1b, IL12p40,MD; E-mail: valentin.
wiss National Foundation
KFS-4281-08-2017), and
be found at https://doi.org/
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could be considered a new
and promising therapeutic
approach in the treatment of
radioresistant melanoma.and RANTES at D9. This was associated with leukocytic infiltration at D9 after MRT,
attributed mainly to CD8 T cells, natural killer cells, and macrophages.
Conclusions: In light of its potential to disrupt blood vessels that promote infiltration
of the tumor by immune cells and its induction of senescence, MRT could be a new
therapeutic approach for radioresistant melanoma.  2019 The Authors. Published
by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Microbeam radiation therapy (MRT) is an alternative ra-
diation therapy technique based on the spatial fractionation
and distribution of the synchrotron x-ray beam into many
microbeams. This configuration allows the deposition of
very high peak doses in the microbeam paths, whereas the
tissue located between the microbeams receives only 1% to
10% of the peak dose (valley dose).1,2 Although the
microbeam peaks cover only w12% to 25% of the irradi-
ated area, the therapeutic efficiency has proven to be high
in small laboratory animals bearing tumors of different
types (EMT6 carcinoma,3 SCCVII carcinoma,4 and 9L
gliosarcoma5-7). Moreover, normal tissues showed only
limited damage in response to the very high peak doses
deposited by microbeams.8,9 The mechanisms and the
chronology underlying the MRT-induced antitumor
response are not well understood, but studies have reported
preferential effects of MRT on immature over mature blood
vessels,10-12 a differential gene expression between MRT
and uniform broad beam (BB) irradiation regarding cell
death,13-15 and effects on immune and inflammatory re-
sponses.16-18
To gain a better understanding of the mechanisms
involved in the efficiency of MRT, a melanoma model was
selected. Malignant melanoma is among the most aggres-
sive cancers, radioresistant and often producing metasta-
ses.19 Conventional radiation therapy, stereotactic
radiosurgery, and spatially distributed (sieve) radiation
therapy have been used, mainly as a palliative strategy for
patients with locally recurrent or metastatic melanoma; this
treatment is efficient in 40% to 50% of patients.20 Radiation
therapy can be prescribed as a first-line treatment in cases
where surgery would result in severe disfigurement or
medical comorbidities (ie, mainly for cutaneous, uveal, or
mucosal melanoma).20
In this study, the antitumor efficacy of MRT on a
radioresistant melanoma was evaluated and compared
with uniform irradiation (BB). The applied BB dose was
equivalent to the MRT valley dose deposited in the tu-
mors. The significantly better tumor control achieved by
MRT has been related to (1) vascular disruption, (2) cell
turnover, and (3) enhanced production of monocyte-
attracting chemokines in the tumor microenvironment,followed by an increased number of tumor-infiltrating
leukocytes.
Methods and Materials
Animals
All experiments were approved by the veterinary office of
the Canton of Bern (BE61/15), and by the ESRF Internal
Evaluation Committee for Animal Welfare and Rights
(14_ethax22). Eight-week-old female C57BL/6J mice
(Charles River Laboratories) were anesthetized by an
intraperitoneal injection of a mixture of fentanyl 0.05 mg/
kg body weight (b.w.), midazolam 5 mg/kg b.w., medeto-
midin 0.5 mg/kg b.w., and 5.6 mL/kg b.w. of sodium
chloride 0.9%. All mice were humanely killed by pento-
barbital intraperitoneal injection (50 mg/kg b.w.) at the end
of the study (ie, 35 days after tumor implantation), or
earlier, for sample collection or if a tumor ulcerated.
Induction of melanoma
Radioresistant B16-F10 melanoma cells,21,22 mixed with a
fibrinogen matrix, were locally implanted in the ears of
C57BL/6J mice, as described previously.23 Briefly, under
anesthesia, 3 skin incisions were made in a square shape on
the ventral surface of the ear. The skin was peeled back, and
a smaller square of the underlying cartilage was removed
and replaced by a “tumor clot” (120000 B16-F10 cells in 4
mL volume, 3 mL of fibrinogen [3 mg/mL, Sigma], and 3 mL
of thrombin [18 U/mL with 2mM CaCl2; Sigma]). The skin
flap was finally repositioned over the clot, and the incisions
were closed with surgical glue (Histoacryl, Braun).
Dosimetry and irradiation
The spatial configuration of the irradiation (microbeams or
uniform BB) was verified using radiochromic film (Gaf-
chromic, HD-810) placed behind the irradiated mouse ear.
The doses were estimated with a Monte Carlo simulation
based on the Geant4 toolkit24 with microbeam fields and
uniform BB fields. The ear of the mouse was modeled as a
0.3 mm thick disk with a 10 mm diameter, composed of
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Fig. 1. Effect of irradiations on melanoma regrowth
delay. Volume curves of tumors irradiated by microbeam
radiation therapy (MRT) (red), by broad beam (BB) (blue),
or nonirradiated (CTRL) (black). Red stars: significant
difference between MRT and BB or CTRL groups. Blue
star: significant difference between BB and CTRL groups.
Black stars: significant difference among the CTRL, MRT,
and BB groups. Mean  standard error of the mean; *P <
.05; ****P < .0001. (A color version of this figure is
available at https://doi.org/10.1016/j.ijrobp.2019.08.027).
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diameter water sphere in the center of the disk. By
comparison with a Monte Carlo simulation performed in a
large homogeneous water phantom, output factors relative
to reference dosimetry conditions25 were identified. Ac-
cording to the calculation, the peak to valley dose ratio
inside the tumor was 65.7.
The irradiations were performed on the ID17 biomedical
beamline at the European Synchrotron Radiation Facility
(ESRF, France) with synchrotron x-rays, as described pre-
viously.9 Ten to 11 days after tumor implantation, mice
were separated into MRT-treated, uniform BB-treated, and
nonirradiated (control) groups. The mice were placed
vertically, with the head retained by a tooth bar and muzzle
clamp. Each ear was fastened by adhesive tape at the ex-
tremity of the ear to avoid any x-ray scattering. For the BB
group, a homogeneous beam 7.5 mm wide and 15 mm high
delivered a dose of 6.2 Gy to the tumor (20.74 Gy/s/mA).
For the MRT group, the irradiation field (7.5 mm wide and
15 mm high) was covered by 37 vertical quasiparallel mi-
crobeams (50 mm wide) produced by an ESRF Multislit
Collimator (50 mm slits, spaced 200 mm apart center to
center). The peak dose deposited in the tumor was 407.6
Gy, and the valley dose was 6.2 Gy (68.78 Gy/s/mA). Mice
in the control group were sham irradiated.
Tumor response
The tumor growth curves, from 2 independent experiments,
were created by measuring the size of the tumors with a
digital caliper. The tumor volume (V, mm3; Fig. 1) was
determined using the formula
VZ
4
3
p  a
2
 b
2
 c
2
where a, b, and c are, respectively, the length, width, and
thickness of the tumor. The tumors were measured 3 days
before irradiation, on the day of irradiation, and then daily
for 20 days. A total of 101 tumors were used to evaluate the
tumor regrowth delay: 47 for MRT, 28 for BB, and 26 in the
control group.
Histologic analyses
Immunofluorescence
At autopsy, all tumors were frozen in isopentane and stored
at e80C. A total of 75 tumors distributed in 5 to 7 tumors
(1 tumor per mouse) per group and per time point (day [D]
e1, 2, 5, 9, and 12) were processed for histology. Immu-
nostaining of endothelial cells (anti-CD31, BD Pharmi-
nogen), proliferating cells (anti-Ki67, Thermo-Fisher
Scientific), T cells (anti-CD4, Abcam; anti-CD8, Abcam),
natural killer (NK) cells (anti-CD161/NK1.1, Novus), and
macrophages (anti-CD68, Biorad) were performed as
detailed in Materials E1 (available online at https://doi.org/
10.1016/j.ijrobp.2019.08.027).To evaluate tumor perfusion, mice were injected with
FITC-albumin (20 mg/mL, 2 mg/kg; Sigma) via the tail
vein; after a circulation period of 1 hour, the tumors were
processed as described in Materials E1 (available online at
https://doi.org/10.1016/j.ijrobp.2019.08.027). Tumor slices
cut from 97 tumors (6-8 tumors/group/time point, 1 tumor
per mouse) were stained with anti-CD31 (BD Pharmi-
nogen) as primary antibody and Alexa Fluor 594 (Molec-
ular Probes) as secondary antibody. This stained endothelial
cells red, and perfused vessels appeared green (Fig. 2D).
Image acquisition and analysis
Fluorescent CD31 immunostained images were acquired
using a Leica M205FA microscope and Leica software LAS
X (objective 10; field of view [FOV]: 1.2614 mm2). An
in-house macro, incorporated into ImageJ software (https://
imagej.nih.gov/ij/), was used to draw the shape of the
CD31-positive vessels, and these images were merged with
the associated FITC-albumin images (Fig. 2D). The number
of vessels (CD31þ) and perfused vessels (CD31þ and
FITC-albuminþ) were reported per FOV.
For the analysis of Ki67, CD4, CD8, CD161/NK1.1, and
CD68 expression, 4 images per tumor (2 central and 2 pe-
ripheral), were obtained using a Zeiss Axioplan2microscope
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ig. 2. Effects of irradiations on melanoma blood vessels. (A) Intratumoral microvascular density has been estimated by
e number of CD31 positive vessels per field of view (FOV). (B) Area of blood vessels per FOV, represented by the total
urface (mm2) occupied by blood vessels. (C) Fractional percentage of perfused blood vessels per FOV. (D) Illustration of the
ethodology. White contours: CD31þ. Green staining: FITC-albuminþ. Arrows: nonperfused vessels (CD31þ and FITC-
lbumine). (E) Concentration of VEGF-a in tumors after microbeam radiation therapy (red), broad beam (blue), or sham-
radiation (black). Mean  standard error of the mean; *P < .05; **P < .01; ***P < .001; ****P < .0001. (A color version
f this figure is available at https://doi.org/10.1016/j.ijrobp.2019.08.027.).
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owith Visiview software (objective 20; FOV: 0.466 mm2).
Proliferating Ki67-positive cells were counted among a
random selection of 100 nuclei stained with DAPI. T cells,
NK cells, and macrophages were evaluated by a scoring
system of 1 to 4, adapted from,9 representative of the
approximate number of immunostained cells (CD4 andCD8:
1, <5%; 2, 5%-12%; 3, 13%-20%; 4, >20%; NK cells and
macrophages: 1, <10%; 2, 10%-20%; 3, 21%-40%; 4,
>40%) (Fig. E1; available online at https://doi.org/10.1016/
j.ijrobp.2019.08.027).
Senescence-associated b-galactosidase staining and
image analysis
Eighty-two tumors were collected, and frozen sections from
5 to 11 tumors/group/time point (1 tumor per mouse) were
stained with senescence-associated b-galactosidase (SA b-
Gal, Sigma) (Materials E1; available online at https://doi.
org/10.1016/j.ijrobp.2019.08.027). Four images per tumor
(objective 10; FOV, 1.45 mm2) were captured with a
Zeiss Imager M2 Light microscope and Cell D software.
Senescent cells were evaluated by a score of 1 to 4, to
represent the approximate tumor area occupied by immu-
nostained cells (0, 0%; 1, 0%-5%; 2, 5%-10%; 3, 10%-
15%; 4, >15%) (Fig. E2; available online at https://doi.org/
10.1016/j.ijrobp.2019.08.027).Enzyme-linked immunosorbent assay and Bio-Plex
analyses
Proteins from 109 tumors (6-12 frozen pieces of tu-
mors/group/time point, 1 tumor per mouse) were
extracted (Material E1; available online at https://doi.
org/10.1016/j.ijrobp.2019.08.027). Tumor tissue ho-
mogenates were tested for a panel of 23 cytokines
(Bio-Plex Pro Mouse Assay, Bio-rad) and VEGF-a
(ELISA kit, LSBio), according to the manufacturers’
instructions. Dilution and analyses are detailed in
Material E1 (available online at https://doi.org/10.1016/
j.ijrobp.2019.08.027). All cytokines without a signifi-
cant difference between MRT and BB groups are pre-
sented in Figure E3 (available online at https://doi.org/
10.1016/j.ijrobp.2019.08.027).Statistical analysis
GraphPad Prism (GraphPad Software, San-Diego, CA) 2-
way analysis of variance with Sidak posttest program was
used. Values were considered significantly different when P
< .05, and results are presented as means  standard error
of the mean.
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Dosimetry
Reference dosimetry in BB configuration was performed
using a PinPoint PTW 31014 ionization chamber (PTW,
Freiburg, Germany). The PinPoint chamber was calibrated
for absorbed dose to water in 60Co and TH200 beam
qualities. The detector was biased at 400 V and read out
using a PTW Unidos Webline electrometer. Correction
factors for ion recombination26 and temperature and pres-
sure27 were determined and applied to the measurements.
Monte Carlo simulations based on the Geant4 toolkit then
were used to convert the reference dose to the dose within
the microbeam field.24
Tumor regrowth delay after MRT and BB irradiation
MRT- and BB-treated mice showed significantly impeded
tumor growth from D5 compared with nonirradiated tumors
(control) (Fig. 1, P < .005). Although almost exponential
growth was seen in the BB-irradiated tumors until the end
of the examination, MRT-treated tumors reached a volume
of 30.4  2.7 mm3 on D4 before the volume decreased
slightly over the next 4 days. MRT-treated tumors regrew
during the next 12 days. The doubling times of tumor
volume were 2.1 days in the control group, 3.7 days in the
BB, and 6 days in the MRT groups.
MRT disrupts tumor vascular perfusion
The immunostaining of CD31-positive endothelial cells
(Fig. E4; available online at https://doi.org/10.1016/j.
ijrobp.2019.08.027) revealed that the number of intra-
tumoral blood vessels did not differ significantly among the
3 groups (Fig. 2A). A tendential increase in the number of
blood vessels was suggested in the MRT-treated group on
D5 (69.7  12 vessels per FOV), but this was not a sig-
nificant difference (P > .05) from the values of 55  6.3
and 47  5.7 vessels per FOV for the BB and control
groups, respectively. The blood vessel area did not differ
among the control, MRT, and BB groups in the first week
after irradiation (Fig. 2B, P > .05). From D9, the BB group
seemed to have larger blood vessels (1355.6  255.1 mm2)
compared with the MRT group (819.3  97.3 mm2). This
difference was significant at D12 (1675.4  245 mm2 for
BB vs 1052.5  123.7 mm2 for MRT, P < .05). Figures 2C
and 2D show the quantification of the blood vessel perfu-
sion, and the fraction of perfused blood vessels in all groups
over all time points was in a range of 80% to 90%. A
notable exception was observed by D5 in the MRT group,
where the percentage of perfused vessels was significantly
lower (68.5%  2.3%) compared with the BB (86.3% 
0.6%, P < .01) and the control groups (81.5%  2.3%, P <
.001; Fig. 2C). Figure 2D shows a representative exampleof perfused vessels (green staining surrounded by white
outline) and nonperfused vessels (with outline indicated by
arrows).
Evaluation of VEGF-a concentration showed a signifi-
cant increase in control tumors (406  59 pg/mL of pro-
tein) compared with irradiated tumors (MRT, 201.4  29
pg/mL of protein, P < .001; BB, 228.8  34.7 pg/mL of
protein, P < .01). On D9, a significant decrease in VEGF-a
concentration was shown in the MRT group (142.6  24.1
pg/mL of protein) compared with the BB group (289.9 
37.9 pg/mL of protein; P < .05; Fig. 2E).
MRT reduces proliferation and induces senescence
of tumor cells
Irradiated tumors showed a decrease in the cell prolifera-
tion index (Ki-67), compared with the control tumors,
starting from D2 in the MRT group (69.8%  3.6% vs
55.8%  2.3%, respectively, P < .05) and from D5 for the
BB group (70.8%  1.9% vs 51.9%  2.3%, respectively,
P < .01) (Fig. 3A). The MRT group showed a significantly
lower tumor cell proliferation rate on D5 compared with the
BB group (23.2%  5.2% vs 51.9%  2.3%, respectively;
P < .0001), with a maximum divergence on D9 (14.5% 
3.6% vs 70.9%  4.8%, respectively; P < .0001).
Figure 3B shows a notable increase of SA-b-gal (senes-
cence marker) in MRT-irradiated tumors. The senescence
index was significantly higher after MRT from D2 to D9
compared with control (P < .01 and P < .0001 at D2 and
D5, respectively) and BB-treated tumors (P < .05, P <
.0001, and P < .001 at D2, D5, and D9, respectively).
MRT significantly enhanced the production of
monocyte-attracting cytokines in the tumor
microenvironment
MRT significantly enhanced the production of monocyte-
attracting cytokines in the tumor microenvironment. The
concentration of chemokines monocyte chemoattractant
protein (MCP)-1, macrophage inflammatory protein (MIP)-
1a, MIP-1b, regulated upon activation normal T cell
expressed and secreted (RANTES), and interleukin (IL)
12p40, which are involved in recruitment and migration of
circulating monocytes in the tumor tissue,28,29 were
significantly higher in the MRT group compared with BB
and control groups (Fig. 4). The concentration of MCP-1
was higher in MRT-treated tumors at D5 (2066.1  188.1
pg/mL of protein) compared with the BB-treated (1406.6 
171.4 pg/mL of protein, P < .05) and the control tumors
(705.3  132.3 pg/mL of protein; P < .0001) (Fig. 4A). At
D9, a significantly higher concentration of MIP-1a (2.56-
fold, P < .05, Fig. 4B), MIP-1b (2.29-fold, P < .05,
Fig. 4C), IL12p40 (2.66-fold, P < .01, Fig. 4D), and
RANTES (2.06-fold, P < .05, Fig. 4E) was observed after
MRT compared with BB irradiation.
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Volume 105  Number 5  2019 Response and mechanisms of MRT on melanoma 1131In MRT-treated tumors, a notably higher presence of im-
mune cells was seen fromD5 toD12 comparedwith the other
groups (Fig. 5). Immunostaining revealed that MRT pro-
moted peritumoral and intratumoral infiltration of macro-
phages, CD4þ and CD8þ T lymphocytes, and NK cells
(Fig. 5). A notably higher presence of these immune cells was
noted at D5 (Fig. 5Bii) and D9 (Fig. 5Biii) in MRT-treated
tumors compared with nonirradiated or BB-treated tumors.Discussion
This study is the first to demonstrate the therapeutic po-
tential of MRT to treat radioresistant melanoma. MRT
transiently suppressed growth and progression of the B16-
F10 mouse melanoma by acting as a tumor vascular dis-
rupting and immunomostimulatory agent. MRT induced
tumor senescence and elicited tumor inflammatory and
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Mean  standard error of the mean; *P < .05; **P < .01; ***P < .001; ****P < .0001. (A color version of this figure is
available at https://doi.org/10.1016/j.ijrobp.2019.08.027.).
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monocyte-attracting chemokines in the tumor
microenvironment.
The relevant radiobiological dose measured during MRT
is a matter of ongoing research. Early studies in MRT used
the peak dose to compare the biological results30,31 because
the peak dose is the most easily accessible quantity. How-
ever, more recent results show that the valley dose is most
likely the deciding factor in regard to biological effects.17,32
This view has been supported by other authors who
demonstrated that (1) the valley dose of MRT is the most
relevant parameter for acute toxicity33 and (2) the inte-
grated dose is not a useful indicator of the biological
equivalence of MRT and BB.34
MRT significantly attenuated melanoma growth during
the 20 days of follow-up, whereas BB irradiation did not
manage to temporarily stop melanoma growth and pro-
gression. Our results are in line with studies previously
published17,35 showing that MRT had superior efficacy in
slowing brain tumor growth in comparison to BB. As
shown recently, a unidirectional microbeam irradiation
(400 Gy and 17.4 Gy as peak and valley doses, respec-
tively) induced better tumor control and survival than BB
irradiation (17.9 Gy) in glioma-bearing rats.17 It was
suggested that part of the better tumor control achieved
by MRT could be attributed to the immediate cell death
caused by the high dose delivered by the micro-
beams.14,17 However, only one-quarter of the total tar-
geted tissue was exposed to the high dose in microbeams,
whereas three-quarters was exposed to the low valley
dose. Therefore, this discrete dose distribution achieved
significant tumor growth delay while sparing the normal
tissue. The latter is particularly important when the tu-
mors are localized in the vicinity of or inside a radio-
sensitive organ.
MRT altered blood vessel integrity and significantly
reduced blood perfusion in irradiated tumors (Fig. 2A),
indicating its potential to act as a vascular disruption agent
in radio-oncology. Studies on chick chorioallantoic mem-
brane and zebrafish caudal fin regeneration models,
showing 2 types of immature vessels, demonstrated that
MRT induced notable morphologic and functional dam-
age10 and severely impaired vascular perfusion12 of
immature blood vessels. Two main mechanisms were
identified: (1) direct disruption of immature capillaries
along the beam path, which caused endothelial cell
detachment and consequent folding into the lumen; and (2)
local adhesion of blood cells at the site of vascular damage.
Importantly, both events interrupted vessel perfusion and
efficiently prevented blood supply even in the first hours
after irradiation. Accordingly, we assume that MRT-based
attenuation of melanoma growth and progression was a
consequence of endothelial cell disruption and inflamma-
tory cell infiltration of irradiated tumors. Moreover, MRT
significantly downregulated the production of VEGF-a
(Fig. 2C), a major proangiogenic cytokine responsible for
tumor expansion and metastasis.36,37 Therefore, bysuppressing VEGF-aedependent neoangiogenesis, MRT
transiently suppressed melanoma growth and progression
(Fig. 1).
According to our results, the significant tumor control
after MRT seems to be linked to the induction of senes-
cence, inflammation, and antitumor immune cell infiltra-
tion. In this study, however, we did not analyze effects of
MRT on the induction of apoptosis because other authors
have found only few apoptotic cells after MRT.14,15 A
significant decrease in the total number of proliferating
cells was observed in MRT-irradiated tumors from D2 to
D12 (Fig. 3A), suggesting that more MRT-irradiated
melanoma cells were either in the G0 phase or dying
rather than in the cell cycle. This event was probably a
result of the MRT-induced senescence of melanoma cells
that was detected from D2 to D9 (Fig. 3B). Senescence
has already been postulated as an important mechanism of
MRT-based antitumor effects against glioma cells.15 The
marker of senescence (b-galactosidase) employed in this
study did not appear to display any changes that reflect the
microbeam pattern; thus, we were not able to observe a
differential effect between the high dose in the peak re-
gion and the low dose in the valley region. Senescent cells
are no longer dividing but are still metabolically active.
They overexpress or secrete proteins in the microenvi-
ronment that influence neighboring cells. This phenotype
is known as the senescence-associated secretory pheno-
type (SASP) and might explain the absence of a differ-
ential effect between the peak and valley dose regions.
The SASP includes the secretion of cytokines, growth
factors, extracellular matrix protease, and immune cells
attracting chemokines.38-40 Here, we noted significantly
elevated levels of MCP-1 and RANTES (Figs. 4), 2 cy-
tokines expressed by senescent melanoma cells39-41 in
MRT-treated tumors. We hypothesize that MRT-induced
senescence promoted the development of SASP in mela-
noma cells, causing the significant increase in the con-
centrations of monocyte-attracting chemokines MCP-1
and RANTES. These 2 chemokines are crucially involved
in the recruitment of leukocytes in the inflamed and ma-
lignant tissues.29 It is well known that irradiation attenu-
ates tumor growth in an MCP-1 dependent manner by
promoting homing of CCR2þ CCR5þ inflammatory
monocytes.29 In a manner similar to MCP-1 and
RANTES, MIP-1a, MIP-1b, and IL-12p40 also promote
migration and influx of inflammatory monocytes from the
peripheral blood in the tumor tissue.27,41,42 As shown in
Figure 4, MRT significantly enhanced the release of these
chemokines, resulting in a massive influx of macrophages,
NK cells, and CD4þ and CD8þ T lymphocytes (Fig. 5).
These immune cells could induce robust inflammatory and
antitumor immune responses through the production of
inflammatory cytokines (by macrophages and CD4þ T
lymphocytes) or via direct cytotoxicity against melanoma
cells (NK cell and CD8þ T lymphocytes), finally resulting
in attenuated melanoma growth and progression.43-45
Moreover, the intratumoral infiltration of these immune
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improved patient survival,46-48 which means MRT has
great potential.
Our study provided evidence thatMRThas a greater effect
on tumor control than does synchrotron BB irradiation. In
addition, a recently published study demonstrated that the
irradiated normal tissue surrounding the tumor is highly
tolerant ofMRT.9Different components of the tumor-bearing
normal tissue, including cutis, subcutis, cartilage, blood, and
lymphatic vessels, demonstrated no significant short- and
long-term morphologic alteration by 400 Gy MRT. High
normal tissue tolerance has been reported recently during
experiments employing BB FLASH radiation therapy. The
work of Favaudon et al in 2014 showed that by using ultra-
high-dose-rate radiation therapy (>40 Gy/s; ie, FLASH),
the normal tissue was spared; irradiation with the same dose
at a lower dose rate (<0.03 Gy/s; conventional) caused
important damage.49 In comparison with conventional radi-
ation therapy, FLASH radiation therapy did not induce lung
fibrosis49 or skin necrosis.50However, the beneficial effect on
tumor controlwas the same for both treatments/49 In contrast,
MRT not only spares normal tissue but also exerts excellent
tumor control. The differential effect between MRT and
FLASH- radiation therapy is probably due to the spatial
distribution of the dose. FLASH-radiation therapy applies a
homogeneous BB dose with a high dose rate, whereas MRT
uses an array of high peak and low valley dose with a high
dose rate.
Conclusions
This study demonstrated superior tumor control byMRTover
BB irradiation of a mouse melanoma model, which is prob-
ably a result of the following events: (1) reduction in the
tumor blood supply by vascular disruption and occlusion; (2)
radiation-disrupted tumor endothelial cells serving as an
entrance site for circulating inflammatory and immune cells;
(3) MRT inducing a decrease in the proliferation index,
associated with induced tumor senescence; (4) senescent
cells seeming to secrete cytokines that initiate infiltration of
different types of immune cells, such as T cells, NK cells, and
macrophages, which are involved in the clearance of senes-
cent cells and thus contribute to tumor control. Accordingly,
MRT represents a promising candidate for new clinical trials,
which should explore the clinical relevance of the MRT-
based antitumor effects presented here.
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